Free tool
FAERS Monitor: Ryzneuta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761134 or its brand name (Ryzneuta, Efbemalenograstim Alfa-Vuxw). Reports on generic versions are filed under their own applications.
Reports
45
Serious
45
100% of reports
Hospitalization
23
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic shock11
- asthenia8
- dizziness7
- chest discomfort5
- dyspnoea5
- nausea5
- hyperhidrosis4
- pyrexia4
- white blood cell count increased4
- blood pressure decreased3
- myelosuppression3
- neutrophil count decreased3
- neutrophil count increased3
- oxygen saturation decreased3
- pallor3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 17 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 11 | 199.6 | 119.4 | 1,981 |
| neutrophil count increasedSignal | 3 | 137.0 | 45.9 | 280 |
| pallorSignal | 3 | 51.5 | 17.3 | 103 |
| white blood cell count increasedSignal | 4 | 48.7 | 19.1 | 143 |
| myelosuppressionSignal | 3 | 38.9 | 13.0 | 76 |
| neutrophil count decreasedSignal | 3 | 34.4 | 11.5 | 67 |
| oxygen saturation decreasedSignal | 3 | 25.0 | 8.4 | 47 |
| chest discomfortSignal | 5 | 22.8 | 10.0 | 84 |
| blood pressure decreasedSignal | 3 | 21.1 | 7.1 | 39 |
| hyperhidrosisSignal | 4 | 14.5 | 5.7 | 38 |
| astheniaSignal | 8 | 9.9 | 5.3 | 57 |
| dizzinessSignal | 7 | 6.6 | 3.3 | 28 |
| pyrexiaSignal | 4 | 5.4 | 2.1 | 10 |
| dyspnoeaSignal | 5 | 4.1 | 1.8 | 9 |
| nauseaSignal | 5 | 3.0 | 1.3 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.